pink-ribbon-14306811601dc-222x300-5897610A bill requiring health plans to cover digital breast tomosynthesis, a three-dimensional type of mammography, has been delivered to Governor Andrew Cuomo’s office for his signature or veto. If the measure is enacted into law, it would be a classic case of healthcare politics rushing ahead of medical science.

Clinical studies have found that 3-D mammograms do a better job of finding potential tumors, especially in the roughly half of women with dense breast tissue, and in avoiding false positive results.

However, the U.S. Preventive Services Task Force has declined to recommend the procedure, citing a lack of long-term research to show that the procedure—which uses a higher dose of radiation than traditional mammography—would lead to better health outcomes.

“The USPSTF concludes that the current evidence is insufficient to assess the benefits and harms of digital breast tomosynthesis (DBT) as a primary screening method for breast cancer,” the agency said in a recommendation published last year.

Despite the scientific uncertainty, Memorial Sloan Kettering Cancer Center and other providers have pushed Albany to mandate insurance coverage for the procedure.

The Cuomo administration responded in February by announcing that it was issuing regulations requiring health plans to cover 3D tomosynthesis “when medically necessary.”

Meanwhile, legislation to impose a broader mandate was introduced by Assemblywoman Rebecca Seawright, D-Manhattan, and Senator Joseph Griffo, R-Rome. Their bill requires coverage of breast tomosynthesis to same extent as traditional mammograms—meaning plans must pay for one “baseline” screening between ages 35 and 39, then at least annual imaging after that.

Because the bill omits mention of medical necessity, plans could not limit the procedure to women with dense tissue, family histories of breast cancer or other risk factors.

The New York Health Plan Association warned that the additional tomosynthesis mandate would increase its members’ costs—and consumers’ premiums—without any demonstrated benefit for patients.

“3-D digital mammography is significantly more expensive than traditional mammography, and there is no evidence to show that 3-D digital mammography should replace traditional mammography as the frontline screening for breast cancer,” the association said in a memorandum of opposition.

Still, the Seawright-Griffo bill passed the Assembly in March and the Senate in June without a single “no” vote. The Legislature formally delivered the bill to Cuomo’s office last Friday, giving him until November 29 to take action.

The bill fits an Albany pattern of imposing coverage mandates based on lobbying by provider or patient groups, but without consulting independent experts. The Legislature voted in 2009 to establish a Health Care Quality and Cost Containment Commission to analyze the costs and benefits of such proposals. But officials never followed through on appointing the panel, and Cuomo eliminated its unused budget earlier this year.

Even for traditional mammograms, New York’s law goes well beyond the recent guidelines of some experts. The Preventive Services Task Force recommends routine screening for women at average risk only every other year from 50 to 74. Noting the downsides of over-diagnosis and unnecessary treatment, the panel says the decision to screen earlier than 50 should be “an individual one”: “Women who place a higher value on the potential benefit than the potential harms may choose to begin biennial screening between the ages of 40 and 49 years.”

About the Author

Bill Hammond

As the Empire Center’s senior fellow for health policy, Bill Hammond tracks fast-moving developments in New York’s massive health care industry, with a focus on how decisions made in Albany and Washington affect the well-being of patients, providers, taxpayers and the state’s economy.

Read more by Bill Hammond

You may also like

Hochul’s ‘Straight Talk’ on Medicaid Isn’t Straight Enough

Arguably the biggest Medicaid news in Governor Hochul's budget presentation was about the current fiscal year, not the next one: The state-run health plan is running substantially over budget. Read More

Despite Lingering Shortages, New York’s Health-Care Workforce Is Bigger Than Ever

The state's health-care workforce is recovering unevenly from the pandemic, with persistently lower employment levels in some areas and robust growth in others. This mixed pattern c Read More

The Wacky Math of New York’s Essential Plan

Thanks to an absurdly wasteful federal law, New York's Essential Plan is expected to continue running billion-dollar surpluses even as state officials more than double its spending over the next several years. Read More

In a Tight Budget Year, New York’s Hospital Lobby Shoots for the Moon

As Governor Hochul calls for spending restraint next year, influential hospital lobbyists are pushing what could be the costliest budget request ever floated in Albany. In a , the G Read More

Putting the Mission in Hochul’s Health Commission

Last week Governor Hochul answered one big question about her Commission on the Future of Health Care – the names of its members – but left a fundamental mystery unresolved:  W Read More

Medicaid Drug ‘Carve-Out’ Led to Double Payments

The state's Medicaid program has effectively been double-paying for prescription drugs for the past six months due to a glitch with the roll-out of its pharmacy "carve-out." Since A Read More

DFS Pulls Back Draft Regulations That Would Have Added a Fee for Prescriptions

A package of proposed regulations that included a $10.18 fee for filling most drug prescriptions was withdrawn Tuesday by the Department of Financial Services in the face of broad opposition. Read More

DeRosa Is Still Hiding the Truth About Cuomo’s Pandemic Response

As the long-time top aide to former Governor Andrew Cuomo, Melissa DeRosa ought to have useful information to share about the state's pandemic response – especially about what went wrong and how the state could be better Read More